Bluebird reveals positive gene therapy data
The therapy targets cerebral adrenoleukodystrophy (CALD), the most severe manifestation of adrenoleukodystrophy (ALD), a rare metabolic disorder.
Read More
Tag: Bluebird
Bluebird bags EU conditional marketing authorisation for Zynteglo
The authorisation for the inherited blood disorder marks bluebird’s first ever drug approval.
Read More
EU regulators to review bluebird’s gene therapy LentiGlobin
The European Medicines Agency will undertake an accelerated review of bluebird bio’s LentiGlobin, a gene therapy for the treatment of transfusion-dependent beta-thalassemia.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
